

CURRICULUM VITAE

CHARLES A. DACKIS, M.D.

PERSONAL INFORMATION

Date of Birth: July 31, 1951
Birthplace: La Crosse, Wisconsin
Home Address: 3 Lawrence Place
Medford, NJ 08055
Home Telephone: (856) 983-9194
Work Address: Penn Behavior Health
3535 Market Street – Room 4036
Philadelphia, PA 19104
Office Telephone: (215) 746-7975
E-mail: dackis@mail.med.upenn.edu
Fax: (215) 746-7979

EDUCATION

1978-1981 Psychiatric Residency: Columbia University, New York
1977-1978 Flexible Internship: Overlook Hospital (a teaching affiliate of Columbia University), Summit, NJ
1973-1977 MD Degree: Duke University School of Medicine
1969-1973 BS Degree in Psychology: Duke University

ACADEMIC POSITIONS

2008-present Associate Professor of Psychiatry
University of Pennsylvania School of Medicine
1999-2008 Assistant Professor of Psychiatry,
University of Pennsylvania School of Medicine
1998-1999 Instructor of Psychiatry,
University of Pennsylvania School of Medicine
1981-1996 Instructor of Psychiatry,
Columbia University College of Physicians and Surgeons

LICENSURE AND CERTIFICATION

License: Pennsylvania #MD052016L
New Jersey #39199 (Inactive)
New York #134856 (Inactive)

Specialty Boards: Certified in Psychiatry: American Board of Psychiatry & Neurology
Certified in Addiction Psychiatry: American Board of Psychiatry
& Neurology (1998-2008)

HONORS

1973 Magna Cum Laude, Duke University
1976 Neuroscience Honors, Duke University Medical School
1980 National Research Service Award Fellow
1981 Laughlin National Award for Merit in Psychiatry
2001 University of Pennsylvania Health System Quality Award
2002 University of Pennsylvania Health System Quality Award
2005 Dean's Award for Excellence in Clinical Teaching
University of Pennsylvania, School of Medicine
2006 Caron Foundation Research Award
2009 Scott Mackler Addiction Teaching Award
University of Pennsylvania School of Medicine

INVENTIONS

Dackis, C and Gold, M: Method of treating psychostimulant addiction:
U.S. Patent Number 4,935,429, 1990.

CAREER PROFESSIONAL MEMBERSHIPS

American Medical Association
American Psychiatric Association
Burlington County Medical Society
Faculty of 1000 in Medicine
Ocean County Medical Society
New York Academy of Science
South Jersey Psychiatric Association
College for the Prevention of Drug Dependence
College of Physicians of Philadelphia

PROFESSIONAL EXPERIENCE

2007-present Medical Director of Clinical Services, Department of Psychiatry, Hospital
of the University of Pennsylvania, University of Pennsylvania Health
System (UPHS)
2007-present Medical Director, Department of Psychiatry, Clinical Practices of the
University of Pennsylvania
2005-present Director, Charles O'Brien Center for Addiction Treatment, Department of
Psychiatry, UPHS
1999-present Chief of Psychiatry, Penn Presbyterian Medical Center, UPHS
2007-present Medical Board Committee, Hospital of the University of Pennsylvania
Charles A. Dackis, M.D.

1999-present	Principle Investigator, Treatment Research Center, Department of Psychiatry, University of Pennsylvania
2009-present	Director, Penn Forensic Program, Department of Psychiatry, UPHS
1999-present	Steering Committee, Center for Studies in Addiction University of Pennsylvania Medical School
1999-present	Medical Executive Committee, Presbyterian Medical Center, UPHS
1999-present	Effectiveness and Quality Committee, Penn Presbyterian, UPHS
1999-2002	Medical Director – Addiction Treatment Unit, Penn Presbyterian, UPHS
1999-2001	Steering Committee – Penn Friends Managed Care Organization Department of Psychiatry, UPHS
1998-1999	Medical Director – Inpatient Psychiatric Unit, Penn Presbyterian, UPHS
1994 - 1998	Medical Director, Shoreline Behavioral Health, Toms River, New Jersey
1994 - 1998	Board Member, Shoreline Behavioral Health System
1995 - 1998	Board Member, Lighthouse Foundation, Lakewood, New Jersey
1994 - 1998	Director, Adult Psychiatric Unit, Shoreline Behavioral Health
1994 - 1995	Director, Dual Diagnosis Unit, Shoreline Behavioral Health
1986 - 1994	Medical Director, Hampton Health System, Weshampton, New Jersey
1986 - 1994	President, Hampton Medical Staff, Hampton Health System
1992 - 1994	Director, Adult Psychiatric Unit, Hampton Health System
1986 - 1992	Director, Neuropsychiatric Evaluation Services, Hampton Health System
1986 - 1987	Media Spokesperson, New Jersey Psychiatric Association
1986 - 1988	Consultant to the National Football League (NFL) for Substance Abuse Detection and Treatment
1982 - 1986	Director, Neuropsychiatric Evaluation Unit, Fair Oaks Hospital Summit, New Jersey
1981 - 1986	Psychiatric Consultant, Alcohol Rehabilitation Unit Fair Oaks Hospital
1981 - 1982	Director of Outpatient Services, Psychiatric Associates of New Jersey Summit, New Jersey
1979 - 1981	Attending Physician, Alcohol and Drug Detoxification Unit Roosevelt Hospital, New York, New York
1975 - 1976	Research Investigator, Department of Psychiatry and Neurology Duke University
1972 - 1977	Research Assistant, Department of Psychology, Duke University

ACADEMIC COMMITTEES AT THE UNIVERSITY OF PENNSYLVANIA

2005 to present	Penn Medical School Curriculum Committee
2005 to present	Penn Psychiatry Resident Steering Committee
2005 to present	Brain & Behavior Committee, University of Pennsylvania Medical School
2006 to 2007	Confidentiality Committee, UPHS
1999 to 2006	Penn School of Medicine Admissions Interview Panel
2000 to 2005	Psychiatric Clerkship Steering Committee
1999 to 2005	Doctoring Course Steering Committee
2002 to 2005	Psychiatric Inpatient Clerkship Committee
2000 to 2001	Robert Wood Johnson Foundation Clinical Scholar Planning Committee
2000 to 2003	Community Psychiatry Residency Rotation Planning Committee

Charles A. Dackis, M.D.

2000 to 2001

Chair, Clinical Committee, Penn Psychiatry Strategic Planning

MAJOR TEACHING ACTIVITIES

1. Director, Addiction Course for Penn Medical Students, Brain & Behavior Block, University of Pennsylvania Medical School (2005-present)
2. General Ambulatory Program (GAP) Director, Penn Psychiatry Residency Program (2009-present)
3. Lecturer, Psychotherapy in Addictive Illness, Penn Psychiatric Residency Program (2001- present)
4. Site Organizer, Brain & Behavior Student-Patient Interviews (1999 –present)
5. Examiner, Penn and Emory Residency Mock Boards (2000–2008)
6. Course Director, “Nuts & Bolts of Psychiatry” Course for Penn Medical Students University of Pennsylvania School of Medicine (2004-2007)
7. Preceptor, Doctoring Course for Penn Medical Students, University of Pennsylvania Medical School (1999–2004)
8. Supervisor, Penn Psychiatry Residents at Penn Presbyterian (1998-2004)
9. Site Director, Psychiatric Clerkships for Penn Medical Students, Penn Presbyterian, UPHS (2002-2003)
10. Course Director – Community Psychiatry Rotation, Penn Psychiatric Residency Program (2000-2002)
11. Co-Director, Advanced Topics in Psychiatry, Administrative Psychiatry Course, Penn Psychiatric Residency Program (2001)
12. Director, Addiction Course for Psychiatric Residents Columbia University (1990-1996)

BIBLIOGRAPHY

Research Publications:

1. Schiffman, S. and C.A. Dackis. Taste of nutrients; Amino acids, vitamins, and fatty acids. Perception and Psychophysics 7(2):140-146, 1975.
2. Schiffman, S. and C.A. Dackis. Multidimensional scaling of musks. Physiology and Behavior 17:823-829, 1976.
3. Sullivan, J., Dackis, C.A. and C. Stanfield. In vivo inhibition of platelet MAO activity by tricyclic antidepressants. American Journal of Psychiatry 134:188-190, 1977.
4. Sullivan, J., Stanfield, C., and C.A. Dackis. Platelet MAO activity in schizophrenia and other psychiatric illnesses. American Journal of Psychiatry 134:1098-1102, 1977.
5. Schiffman, S., Nash, M. and C.A. Dackis. Reduced olfactory discrimination in patients on chronic hemodialysis. Physiology and Behavior 21:239-242, 1978.

6. Dackis, C.A., Pottash, A.L.C., Annitto, W.J. and M.S. Gold. Persistence of urinary marijuana levels after supervised abstinence. American Journal of Psychiatry 139:1196-1198, 1982.
7. Dackis, C.A., Gurpegui, M., Pottash, A.L.C. and M.S. Gold. Methadone-induced hypoadrenalism. Lancet 2:1167, 1982.
8. Dackis, C.A., Pottash, A., Bailey, J., Stuckey, R., Extein, I., and M.S. Gold. The specificity of the thyrotropin-releasing hormone (TRH) test and dexamethasone suppression test (DST) for major depressive illness in alcoholics. National Institute of Drug Abuse Research Monograph Series 43:266-272, 1983.
9. Dackis, C.A. and M.S. Gold. Opiate addiction and depression - cause or effect? Drug and Alcohol Dependence 11:105-109, 1983.
10. Hamlin, C.L., Lydiard, R.B., Martin, D., Dackis, C.A., Pottash, A.L.C., Sweeney, D.L. and M.S. Gold. Urinary excretion of noradrenaline metabolite decreased in panic disorder. Lancet 2:740-741, 1983.
11. Dackis, C.A., Pottash, A.L.C., Gold, M.S., and W.J. Annitto. The dexamethasone suppression test for major depression among opiate addicts. American Journal of Psychiatry 141:810-811, 1984.
12. Demilio, L., Dackis, C.A., Gold, M.S., and J.R. Ehrenkranz. Addison's disease initially diagnosed as bereavement and conversion disorder. American Journal of Psychiatry 141:1647-1648, 1984.
13. Dackis, C.A., Bailey, J., Pottash, A.L.C., Stuckey, R.F., Extein, I.L. and M.S. Gold. Specificity of the DST and TRH test for major depression in alcoholics. American Journal of Psychiatry 141:680-682, 1984.
14. Dackis, C.A. and M.S. Gold. New concepts in cocaine addiction: The dopamine depletion hypothesis. Neuroscience and Biobehavioral Reviews 9:469-477, 1985.
15. Dackis, C.A. and M.S. Gold. Bromocriptine as a treatment of cocaine abuse. Lancet 1:1151-1152, 1985.
16. Dackis, C.A., Estroff T., Sweeney, D.L., Pottash, A.L.C. and M.S. Gold. Thyroid axis abnormalities in cocaine abuse. National Institute of Drug Abuse Research Monograph Series 55:254-257, 1985.
17. Dackis, C.A., Pasternak-Dackis, M., Martin, D., Pottash, A.L.C. and M.S. Gold. Platelet serotonin transporter in cocaine patients. National Institute of Drug Abuse Research Monograph Series 55:164-169, 1985.

18. Dackis, C.A., Estroff, T.W., Sweeney, D.R., Pottash, A.L.C. and M.S. Gold. Specificity of the TRH test for major depression in patients with serious cocaine abuse. American Journal of Psychiatry 142:1097-1099, 1985.
19. Dackis, C.A., Stuckey, R., Pottash, A.L.C. and M.S. Gold, M. Dexamethasone suppression test testing of depressed alcoholics. Alcoholism: Clinical and Experimental Research 10(1):59-60, 1986.
20. Cocores, J. A., Dackis, C.A., Davies, R.K., and M.S. Gold. Propranolol and stuttering. American Journal of Psychiatry 143(10):1309-1310, 1986.
21. Dackis, C.A., Pottash, A.L.C., Gold, M.S., and D.R. Sweeney. Evaluating depression in alcoholics. Psychiatry Research 17:105-109, 1986.
22. Cocores, J.A., Dackis, C.A., and M.S. Gold. Sexual dysfunction secondary to cocaine abuse in two patients. Journal of Clinical Psychiatry 47:384-385, 1986.
23. Dackis, C.A., Gold, M.S., Sweeney, D.R., Byron, J. and R. Climko. Single-dose bromocriptine reverses cocaine craving. Psychiatry Research 20:261-264, 1986.
24. Dackis, C.A., Yu, E., Samaha, F., Kampman, K., Cornish, J., Rowan, M., Gerhart, M., Barnes, L., White, L., Poole, S., and C.P. O'Brien. Modafinil – cocaine safety study: A double blind, placebo-controlled drug interaction study. Drug and Alcohol Dependence 70(1):29-37, 2003.
25. Kampman, K.M., Majewska, M.D., Tourian, K., Dackis, C.A., Cornish, J., Poole, S. and C.P. O'Brien. A pilot trial of piracetam and ginkgo biloba for the treatment of cocaine dependence. Addictive Behaviors 28:437-448, 2003.
26. Dackis, C.A. and C.P. O'Brien. Glutamatergic Agents for Cocaine Dependence. Annals NY Academy of Science 1003:328-345, 2003.
27. Kampman, K.M., Pettinati, H., Lynch, K.G., Dackis, C.A., Sparkman, T., Weigley, C. and C.P. O'Brien. A pilot trial of topiramate for the treatment of cocaine dependence. Drug and Alcohol Dependence 75:233-240, 2004.
28. Dackis, C.A., Kampman, K.M., Lynch, K.G., Pettinati, H.M., Klein, L.J., McAllister, M.H., Smith, K.J., and C.P. O'Brien. A double-blind, placebo-controlled trial of modafinil in cocaine dependence. Neuropsychopharmacology 29:S72, 2004.
29. Dackis, C.A., Kampman, K.M., Lynch, K.G., Pettinati, H.M., and C.P. O'Brien. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 30:205-211, 2005.
30. Comer, S.D., Sullivan, M.A., Yu, E., Rothenberg, J.L., Kleber, H.D., Kampman, K., Dackis, C.A., O'Brien, C.P., Chiang, N.C. and R.L. Hawks. Injectable, sustained-

release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Archives of General Psychiatry 63(2):210-218, 2006.

31. Dahl, J.P., Cubells, J. F., Ray, R., Weller, A. E., Lohoff, F. W., Ferraro, T. N., Oslin, D. W., Kampman, K. M., Dackis, C.A., Tang, Y., Gelernter, J., Kranzler, H. R., O'Brien, C. P., and W.H. Berrettini. Analysis of variations in the tryptophan hydroxylase-2 (TPH2) gene in cocaine dependence. Addiction Biology 11(1):76-83, 2006.
32. Kampman, K.M., Dackis, C.A., Lynch, K.G., Pettinati, H.M., Tirado, C., Gariti, P., Sparkman, T., Atzram, M., and C.P. O'Brien. A double-blind, placebo-controlled trial of amantadine and propranolol for the treatment of cocaine dependent patients with severe cocaine withdrawal symptoms. Drug and Alcohol Dependence 85(2): 129-137, 2006.
33. Weller A.E., Dahl J.P., Lohoff F.W., Kampman K.M., Oslin D.W., Dackis, C.A., Ferraro, T.N., O'Brien C.P., and W.H. Berrettini. No association between polymorphisms in the prostate apoptosis factor-4 gene and cocaine dependence. Psychiatric Genetics 2006; 16(5):193-196, 2006.
34. Ahmadi, J., Kampman, K.M., and C.A. Dackis. Outcome predictors in cocaine dependence treatment trials. American Journal of Addictions 15(6):434-9, 2006.
35. Kampman, K.M., Pettinati, H.M., Lynch, K.G., Whittingham, T., Macfadden, W., Dackis, C., Tirado, C., Oslin, D.W., Sparkman, T., O'Brien, C.P. A double-blind, placebo-controlled pilot trial of quetiapine for the treatment of Type A and Type B alcoholism. Journal of Clinical Psychopharmacology 27(4):344-51, 2007.
36. Amhadi, J., Kampman, K., Dackis, C., Sparkman, T., & Pettinati, H.M. Cocaine withdrawal symptoms identify Type B "cocaine" dependent patients. American Journal on Addictions 17(1):60-64, 2008.
37. Pettinati, H.M., Kampman, K.M., Lynch, K.G., Suh, J.J., Dackis, C.A., Oslin, D.W., and C.P. O'Brien. Gender differences with high-dose naltrexone in the patient with co-occurring cocaine and alcohol dependence. Journal of Substance Abuse Treatment 34:378-390, 2008.
38. Schnoll, R.A., Wileyto, E.P., Pinto, A., Leone, F., Gariti, P., Siegel, S., Perkins, K.A., Dackis, C., Heitjan, D.F., Berrettini, W., and C. Lerman. A placebo controlled trial of modafinil for nicotine dependence. Drug and Alcohol Dependence 98:86-93, 2008.
39. Lohoff, F.W.; Bloch, P.J., Weller, A.E., Nall, A.H., Doyle, G.A., Buono, R.J., Ferraro, T.N., Kampman, K.M., Pettinati, H.M., Dackis, C.A., Oslin, D.W., O'Brien, C.P., Berrettini, W.H. Genetic variants in the cocaine- and amphetamine-regulated transcript gene (CARTPT) and cocaine dependence. Neuroscience Letters:440(3):280-3, 2008.

40. Lohoff, F.W., Weller, A.E., Bloch, P.J., Nall, A.H., Ferraro, T.N., Kampman, K.M., Pettinati, H.M., Oslin, D.W., Dackis, C.A., O'Brien, C.P., and W.H. Berrettini. Association between the catechol-O-methyltransferase Val158Met polymorphism and cocaine dependence. Neuropsychopharmacology 33: 3078-84, 2008.
41. Pettinati, H.M., Kampman, K.M., Lynch K.G., Xie, H., Dackis, C., Rabinowitz, A.R., and C.P. O'Brien. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addictive Behaviors 33:651-667, 2008.
42. Oslin, D.W., Lynch, K.G., Pettinati, H.M., Kampman, K.M., Gariti, P., Gelfand, L., Ten, H.T., Wortman, S., Dundon, W., Dackis, C.A., Volpicelli, J.R., and C.P. O'Brien. □A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention. Alcoholism, Clinical and Experimental Research 2008:32(7):1299-308, 2008.
43. Amhadi, J., Kampman, K., Oslin, D.M., Dackis, C., Sparkman, T., Pettinati, H.M Predictors of treatment outcome in outpatient cocaine and alcohol dependence treatment. American Journal of Addiction 18:81-86, 2009.
44. Kampman, K.M., H. M. Pettinati, H.M., Lynch, K.G., Xie, H., Dackis, C.A., Oslin, D.W., Sparkman, T., Sharkoski, T., and C.P. O'Brien. Initiating acamprostate within-detoxification versus post-detoxification in the treatment of alcohol dependence. Addict Behaviors 34 (6-7):581-6, 2009.
45. Anderson, A.L., Reid, M.S., Li, S.H., Holmes, T., Shemanski, L., Slee, A., Smith, E.V., Kahn, R., Chiang, N., Vocci, F., Ciraulo, D., Dackis, C.A., Roache, J. D., Salloum, I. M., Somoza, E., Urschel, H. C., and A.M. Elkashef, Modafinil for the treatment of cocaine dependence. Drug and Alcohol Dependence, 104(1-2):133-9, 2009.
46. Bloch, P., Nall, A., Weller, A., Ferraro, T., Berrettini, W., Kampman, K., Pettinati, H., Dackis, C., O'Brien, C., Oslin, D., and F. Lohoff, Association analysis between polymorphisms in the dopamine D3 receptor (DRD3) gene and cocaine dependence. Psychiatric Genetics, 2009. 19(5): p. 275-6.
47. Lohoff, F.W., Bloch, P. J., Ferraro, T. N., Berrettini, W. H., Pettinati, H. M., Dackis, C. A., O'Brien, C. P., Kampman, K. M., and D.W. Oslin, D. W. Association analysis between polymorphisms in the conserved dopamine neurotrophic factor (CDNF) gene and cocaine dependence. Neuroscience Letter, 2009. 453(3): p. 199-203.
48. Lohoff, F.W., Bloch, P. J., Hodge, R., Nall, A. H., Ferraro, T. N., Kampman, K. M., Dackis, C. A., O'Brien, C. P., Pettinati, H. M., and D.W. Oslin. Association analysis between polymorphisms in the dopamine D2 receptor (DRD2) and

- dopamine transporter (DAT1) genes with cocaine dependence. Neuroscience Letter, 2010, in press
49. Pettinati, H.M., Oslin, D.W., Kampman, K.M., Dundon, W.D., Xie, H., Gallis, T.L., Dackis, C.A.; C.P. O'Brien. A Double-Blind, Placebo-Controlled Trial Combining Sertraline and Naltrexone for Treating Co-Occurring Depression and Alcohol Dependence. American Journal of Psychiatry, 2010 (in press).

Editorials, Reviews, Chapters:

1. Gold, M.S., Dackis, C.A., Pottash, A.L.C., Sternback, H.S., Annitto, W.J., Martin, D., and M.A. Pasternak-Dackis. Naltrexone, opiate addiction, and endorphins. Medicinal Research Reviews 2:211-246, 1982.
2. Dackis, C.A., Pottash, A.L.C., and M.S. Gold. Is there "reverse tolerance" to marijuana? (letter) American Journal of Psychiatry 140:655-656, 1983.
3. Gold, M.S., and Dackis, C.A. The discovery of clonidine's action in opiate withdrawal, in Bock, K.D. (Ed.) Catapressan, Arsneimittel-Forschung, Munich, 1983, pp. 155-175.
4. Dackis, C.A., Bailey, J., Pottash, A.L.C., Stuckey, R.F., and Gold, M.S. Accuracy of dexamethasone suppression test in alcoholics. Archives of General Psychiatry 40:586-587, 1983.
5. Gold, M.S., Dackis, C.A., and Washton, A.M. The sequential use of clonidine and naltrexone in the treatment of opiate addicts. Advances in Alcohol and Substance Abuse 3(3):19-39, 1984.
6. Gold, M.S., and Dackis, C.A. New insights and treatments. Opiate withdrawal and cocaine addiction. Clinical Therapies 7(1):6-21, 1984.
7. Dackis, C.A., Pottash, A.L.C., and Gold, M.S. Recent alcohol abstinence and the dexamethasone suppression test. American Journal of Psychiatry 141:1643-1644, 1984.
8. Dackis, C.A., and Gold, M.S. Depression in opiate addicts, in Mirin, SM (Ed.) Substance Abuse and Psychopathology, American Psychiatric Press, Washington, DC, 1984, pp. 19-40.
9. Dackis, C.A., and Stuckey, R.F. Psychopharmacological treatment of the alcoholic. Psychiatry Letter 2(7): 45-50, 1984.
10. Dackis, C.A., and Gold, M.S. The serotonin subtype of depression, in Gold, M.S., Lydiard, R.B., and Carman, J.S. (Eds.) Advances in Psychopharmacology, CRC Press, Boca Raton, 1984, pp. 107-120.

11. Dackis, C.A., Gold, M.S., Davies, R.K., and Sweeney, D.R. Bromocriptine treatment for cocaine abuse: the dopamine depletion hypothesis. International Journal of Psychiatry in Medicine 15:125-135, 1985.
12. Gold, M.S., Washton, A.M., and Dackis, C.A. Cocaine abuse: Neurochemistry, phenomenology, and treatment. National Institute of Drug Abuse, Research Monograph Series 61:130-150, 1985.
13. Dackis, C.A., and Gold, M.S. Bromocriptine treatment of cocaine abuse. Psychiatry Letter 3(8):45-50, 1985.
14. Gold, M.S., Verebey, K., and Dackis, C.A. Diagnosis of drug abuse, drug intoxication and withdrawal states. Psychiatry Letter 3(5):23-34, 1985.
15. Dackis, C.A., and Gold, M.S. Pharmacological approaches to cocaine addiction. Journal of Substance Abuse Treatment 2:139-145, 1985.
16. Estroff, T.W., Dackis, C.A., Gold, M.S., and Pottash, A.L.C. Drug abuse and bipolar disorders. International Journal of Psychiatry in Medicine 15:37-40, 1985.
17. Gold, M.S., Semlitz, L., Dackis, C.A., and Extein, I.L. The adolescent cocaine epidemic. Seminars in Adolescent Medicine 1(4):303-309, 1985.
18. Gold, M.S., Hamlin, C.L., and Dackis, C.A. Protirelin testing in psychiatry, in Giannini, A.J. (Ed.) The Biological Foundations of Clinical Psychiatry. Elsevier Science Publishing Company, New York, 1986, pp. 191-201.
19. Gold, M.S. and Dackis, C.A. Role of the laboratory in the evaluation of suspected drug abuse. Journal of Clinical Psychiatry 47(1):17-23, 1986.
20. Gold, M.S., Dackis, C.A., Pottash, A.L.C., Extein, I.L., and Washton, A. Cocaine update: from bench to bedside. Advances in Alcohol and Substance Abuse 5:35-60, 1986.
21. Dackis, C.A., Gold, M.S., Pottash, A.L.C., and Annitto, W.J. Depression in opiate addicts. American Journal of Psychiatry 143:119-120, 1986.
22. Gold, M.S., Washton, A.M., Dackis, C.A., and Chatlos, J.C. New treatments for opiate and cocaine users: But what about marijuana? Psychiatric Annals 16(4): 206-214, 1986.
23. Dackis, C.A. Substance Abuse and Psychopathology (book review). Journal of Studies on Alcohol 47:263-264, 1986.
24. Extein, I.L., Dackis, C.A., Gold, M.S., and Pottash, A.L.C. Depression in drug addicts and alcoholics, in Extein, I.L., and Gold, M.S. (Eds.) Medical Mimics of

- Psychiatric Disorders, American Psychiatric Press, Washington, DC, 1986, pp. 131-162.
25. Dackis, C.A., and Gold, M.S. The self-medication hypothesis of addiction (letter). American Journal of Psychiatry 143:10, 1309-1310, 1986.
 26. Dackis, C.A., Gold, M.S., and Sweeney, D.R. The physiology of cocaine craving and "crashing." (letter) Archives of General Psychiatry 44:298-300, 1987.
 27. Roehrich, H., Dackis, C.A., and Gold, M.S. Bromocriptine. Medicinal Research Reviews 7(2):243-269, 1987.
 28. Miller, N., Dackis, C.A., and Gold, M.S. The relationship of addiction, tolerance, and dependence to alcohol and drugs: A neurochemical approach. Journal of Substance Abuse Treatment 4:197-207, 1987.
 29. Dackis, C.A., Gold, M.S., and Pottash, A.L.C. Central stimulant abuse: Neurochemistry and pharmacotherapy. Advances in Alcohol and Substance Abuse 6(2):7-21, 1987.
 30. Dackis, C.A., Gold, M.S. Neurotransmitter and neuroendocrine abnormalities associated with cocaine use. Psychiatric Medicine 4(3):461-483, 1987.
 31. Extein, I.L., and Dackis, C.A. Brain mechanisms in cocaine dependency, in Washton, A., and Gold, M.S. (Eds.) Cocaine: A Clinician's Handbook, Gilford Press, New York and London, 1988, pp. 73-84.
 32. Annitto, W.J., and Dackis, C.A. Opinion: Clinical use of urine testing in relapse prevention. The Journal of the Medical Society of New Jersey 85(10):829-831, 1988.
 33. Dackis, C.A., and Gold, M.S. Psychopharmacology of cocaine. Psychiatric Annals 18(9):528-530, 1988.
 34. Dackis, C.A., and Gold, M.S. Treatment of addiction on a psychiatric unit (Chapter 19) in Giannini, A. and A. Slaby (Eds.) Drugs of Abuse, Medical Economics Books, Oradell, 1989, pp. 367-379.
 35. Dackis, C.A., and Gold, M.S., Estroff, T.W. Inpatient treatment of addiction (Chapter 137) in Treatments of Psychiatric Disorders: A Task Force Report of the American Psychiatric Association, 1989, pp. 1359-1379.
 36. Dackis, C.A., and Gold, M.S. Medical, endocrinological, and pharmacological aspects of cocaine addiction, in Volkow, N., and Swann, A. (Eds.) Cocaine in the Brain, Rutgers University Press, New Brunswick and London, 1990, pp. 135-154.

37. Dackis, C.A., and Gold, M.S. Addictiveness of central stimulants. Advances in Alcoholism and Substance Abuse 9:9-26, 1990.
38. Annitto, W.J., and Dackis, C.A. Use of Benzodiazepines by alcoholics (letter). American Journal of Psychiatry 147:1, 1990.
39. Dackis, C.A., and Gold M.S. Psychopathology resulting from substance abuse (Chapter 12), Slaby, A.E. and M.S. Gold (Eds.) in Dual Diagnosis in Substance Abuse, Marcel Dekker, Inc., New York, pp. 205-222, 1991.
40. Dackis, C.A., and Gold, M.S. Inpatient treatment of drug and alcohol addiction (Chapter 67), Miller, N. (Ed.) in Comprehensive Handbook of Drug and Alcohol Addiction, Marcel Dekker, Inc., New York, 1991, pp. 1233-1244.
41. Dackis, C.A. and Gold, M.S. Treatment strategies for cocaine detoxification (Chapter 19) in Lakoski, J., Galloway, M. and F. White, F. (Eds.) Cocaine: Pharmacology, Physiology and Clinical Strategies, CRC Press, Boca Raton, 1992, pp. 411-426.
42. Dackis, C.A., and Gold, M.S. Psychiatric hospitals for treatment of dual diagnosis (Chapter 36), in Lowinson, J., Ruiz, P., Millman, R., & Langrod, J. (Eds.) Substance Abuse, A Comprehensive Textbook, Williams & Wilkins, Baltimore, 1992, pp. 467-485.
43. Dackis, C.A. and O'Brien, C.P. Traitement de la dépendance à la cocaïne: une maladie du circuit de récompense encéphalique. La Cène 4-5:34-40, 2000.
44. Dackis, C.A. and O'Brien, C.P. Cocaine dependence: A disease of the brain's reward centers. Journal of Substance Abuse Treatment 21:111-117, 2001.
45. Dackis, C.A. A commentary on the role of laboratory tests for alcoholism treatment. Journal of Substance Abuse Treatment 20:87-88, 2001.
46. Dackis, C.A. and C.P. O'Brien. Treatment of cocaine, an overview (Volume 3) in DeWitt, R.C. (Ed.) Encyclopedia of Drugs, Alcohol, and Addictive Behavior, Revised Edition, Macmillan Publishing, New York, 2001, pp. 1157-62.
47. Dackis, C.A. and O'Brien, C.P. Cocaine dependence: the challenge for pharmacotherapy. Current Opinion in Psychiatry 15:261-267, 2002.
48. Forman, R.F., Dackis, C.A., Rawson, R. Twelve principles of outpatient addiction treatment. Current Psychiatry 1(6):16-24, 2002.
49. Dackis, C.A. and O'Brien, C.P. The neurobiology of addiction in Asbury, A.K., McKhann, G.M., McDonald, W.I., Goadsby, P.J. and J.C. McArthur (Eds.) Diseases of the Nervous System (Third Edition), Cambridge University Press, Cambridge, 2002, pp. 431-444.

50. Dackis, C.A. and O'Brien, C.P. The neurobiology of alcoholism in Gershon, S. and Soares, J. (Eds.) Handbook of Medical Psychiatry, Marcel Dekker, New York, 2003, pp. 563-580.
51. Dackis, C.A. and O'Brien, C.P. Neurobiology of cocaine dependence limits development of pharmacological treatments. Psychiatry Annals 33(9):565-570, 2003.
52. Dackis, C.A. and Miller, N. Neurobiological effects determine treatment options for alcohol, cocaine, and heroin addiction. The neurobiology and pharmacology of addiction. Psychiatry Annals 33(9):585-592, 2003.
53. Dackis, C.A. and O'Brien, C.P. Pharmacotherapy of adolescent substance dependence. Child and Adolescent Psychopharmacology News 9(2):1-6, 2004.
54. Dackis, C.A. Recent advances in the pharmacotherapy of cocaine dependence. Current Psychiatry Reports 6:323-331, 2004.
55. Dackis, C.A. New treatments for cocaine abuse. Drug Discovery Today 2(1):79-86, 2005.
56. Dackis, C.A. and O'Brien, C.P. Clinical implications of cocaine-induced cortical depression (letter). Neuropsychopharmacology 3(5):1033, 2005.
57. Dackis, C.A., Lynch, K.G., Kampman, K.M., Pettinati, H.M., and O'Brien, C.P. Response to letter to the editor: Do self-reports reliably assess abstinence in cocaine dependent patients? Neuropsychopharmacology 30(12): 2299-2300, 2005.
58. O'Brien, C.P., Anthony, J.C., Carroll, K., Childress, A.R., Dackis, C.A., Diamond, G., Hornik, R., Johnston, L.D., Jones, R., Koob, G.E., Kosten, T., Lerman, C., McLellan, A.T., Moss, H., Pettinati, H. and Spoth, R. Defining substance use disorders in Evans, D.L., Foa, E.B., Gur, R.E., Hendin, H., O'Brien, C.P., Seligman, M.E.P., and Walsh, B.T. (Eds.) Treating and Preventing Adolescent Mental Health Disorders. Oxford University Press, Oxford, 2005, pp. 336-426.
59. Dackis, C. and O'Brien, C. Neurobiology of addiction: treatment and public policy ramifications. Nat Neurosci 8(11): 1431-6, 2005.
60. O'Brien, C.P., Dackis, C.A., and K. Kampman. Does modafinil produce euphoria? American Journal of Psychiatry 163(6):1109, 2006.
61. Detoxification and Substance Abuse Treatment, Treatment Improvement Protocol (TIP) Series # 19 (revision). Consensus Panel member. Norman Miller,

62. Pettinati H.M., O'Brien C.P., Rabinowitz A.R., Wortman S.P., Oslin D.W., Kampman K.M., and Dackis, C.A. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking. Journal of Clinical Psychopharmacology 26(6): 610-25, 2006.
63. Steen, T.A. and Dackis, C.A. Treatment of cocaine dependence, in Smith, H and S. Passik (Eds.) Pain and Chemical Dependency Textbook, Oxford University Press, New York, 2008, 145-151.
64. Dackis, C.A. and O'Brien, C.P. Normalizing effects of modafinil on sleep in chronic cocaine users. American Journal of Psychiatry 16, 2010 (in press)
65. Dackis, C.A. and O'Brien, C.P. Integrating naltrexone treatment with Alcoholics Anonymous, Journal of Addiction Medicine, 2010 (in press).

Abstracts:

Pheterson, A.D., Dackis, C.A., Sweeney, D.R., and Gold, M.S. Plasma cortisol levels in opiate addicts before and after detoxification. Society for Neuroscience 9: 123.11, 1983.

Dackis, C.A., Gold, M.S., Pottash, A.L.C., Bailey, J., Annitto, W., and Stuckey, R.F. Depression in alcoholism and opiate addiction. American Psychiatric Association Symposium 60, 1983.

Gurpegui, M., Dackis, C.A., and Gold, M.S. ACTH stimulation test in methadone addicts. American Psychiatric Association Abstract 37, 1983

Dackis, C.A., Pottash, A.L.C., Bailey, J., Stuckey, R.F., Extein, I.L., and Gold, M.S. Neuroendocrine testing for depression in alcoholics. American Psychiatric Association Abstract 37, 1983.

Goggans, F.C., Dackis, C.A., Bloodworth, R.C., Pottash, A.L.C., and Gold, M.S. Autoimmune thyroiditis presenting as depression. American Psychiatric Association Abstract 49, 1983.

Gurpegui, M., Dackis, C.A., and Gold, M.S. Depression: Primary and secondary to opiate abuse. 7th World Congress of Psychiatry Abstract, 1983.

Dackis, C.A., Pottash, A.L.C., Annitto, W., and Gold, M.S. DST testing of opiate addicts. American Psychiatric Association New Research Abstract, 1983.

Dackis, C.A., Gold, M.S., Estroff, T.W., and Sweeney, D.R. Hyperprolactinemia in cocaine abuse. Society for Neuroscience Abstract 10:1099, 1984.

Dackis, C.A., Estroff, T.W., Sweeney, D.R., Pottash, A.L.C., and Gold, M.S. TRH testing of cocaine addicts. American Psychiatric Association New Research Abstract, 1984.

Hamlin, C.L., Dackis, C.A., Martin, D.M., Sweeney, D.R., and Gold, M.S. Blunted thyrotropin releasing hormone stimulation test in panic disorders. American Psychiatric Association Abstract 4, 1984.

Estroff, T.W., Dackis, C.A., Sweeney, D.R., Gold, M.S., and Pottash, A.L.C. Drug abuse and coexistent bipolar disorder. American Psychiatric Association Abstract 36, 1984.

Dackis, C.A., Pottash, A.L.C., and Gold, M.S. DST testing of depressed alcoholics. American Medical Society on Alcoholism Conference Abstract, 1985.

Dackis, C.A., Gold, M.S., and Pottash, A.L.C. Bromocriptine treatment for cocaine withdrawal. Society for Neuroscience Abstract 11, 1985.

Gold, M.S., Dackis, C.A., and Pottash, A.L.C. Dopamine deficiency in cocaine abuse. Society for Neuroscience Abstract 11, 1985.

Dackis, C.A., Pottash, A.L.C., and Gold, M.S. Diagnosing depression in alcoholics. American Psychiatric Association Paper Abstract 33, 1985.

Dackis, C.A., Estroff, T.W., and Gold, M.S. Hyperprolactinemia in cocaine abuse. American Psychiatric Association New Research Abstract 181, 1985.

Extein, I.L., Dackis, C.A., Gold, M.S., and Pottash, A.L.C. Depression in drug addicts and alcoholics. American Psychiatric Association Symposium 87, 1985.

Estroff, T.W., Dackis, C.A., Sweeney, D.R., Pottash, A.L.C., and Kane, M. Neurochemical changes in cocaine and opiate abuse. American Psychiatric Association New Research Abstract 180, 1985.

Cocores, J.A., Dackis, C.A., Davies, R.K., and Gold, M.S. Propranolol and stuttering. IVth World Congress of Biological Psychiatry Abstract, 1985.

Dackis, C.A., Pottash, A.L.C., and Gold, M.S. DST testing of depressed agoraphobics. IVth World Congress of Biological Psychiatry Abstract, 1985.

Dackis, C.A., Sweeney, D.R., Byron, J.A., Climko, R., Gold, M.S., and Pottash, A.L.C. Bromocriptine treatment for cocaine craving. American Psychiatric Association New Research Abstract 71, 1986.

Dackis, C.A., Gold, M.S., and Pottash, A.L.C. Dopamine depletion and cocaine craving. American Psychiatric Association New Research Abstract, 1987.

Dackis, C.A., Gold, M.S., and Annitto, W.J. Cocaine: Medical and brain effects. American Psychiatric Association New Research Abstract, 1988.

Dackis, C.A., Yu, E., Samaha, F., Kampman, K., Cornish, J., Rowan, M., Gerhart, M., Barnes, L., White, L., Poole, S., and O'Brien, C.P. Modafinil – cocaine safety study: A double blind, placebo-controlled drug interaction study. *Drug and Alcohol Dependence*, 63: S37, 2001.

Dackis, C.A., Kampman, K., Pettinati, H., Weigly, C. and O'Brien, C.P. An open-label pilot study on the effectiveness and tolerability of modafinil for cocaine dependence. *Drug and Alcohol Dependence*, 66: S39-40, 2002.

Dackis, C.A., Kampman, K., Pettinati, H., Weigly, C. and O'Brien, C.P. Modafinil treatment of cocaine dependence. *Committee for Problems on Drug Dependence*, 2003.

Dackis, C.A., Kampman, K., Pettinati, H., Weigly, C. and O'Brien, C.P. An open-label pilot study of modafinil for cocaine dependence. American Psychiatric Association New Research Abstract, 2003.

Dackis, C., Lynch, K., Kampman, K., Pettinati, H., Klein, B., McAllister, M, and O'Brien, C.P. Modafinil improves cocaine abstinence in cocaine-dependence: a double-blind, placebo-controlled trial. An open-label pilot study of modafinil for cocaine dependence. NCDEU Abstract, 2004.

Dackis, C., Lynch, K., Kampman, K., Pettinati, H., Klein, B., McAllister, M, and O'Brien, C.P. Modafinil treatment for cocaine abstinence, *Committee for Problems on Drug Dependence*, 2004.

Dackis, C.A., Kampman, K. M., Lynch, K. G., Pettinati, H. M., Klein, L. J., McAllister, M.H., Smith, K.J., and O'Brien, C.P. A double-blind, placebo-controlled trial of modafinil in cocaine dependence. *American College of Neuropsychopharmacologists Annual Meeting*, San Juan, 2004.

Kampman, K.M., Pettinati, H.M., Lynch, K.G., Dackis, C.A., Aztram, M., McAllister, M. O'Brien, C.P. Predictors of outcome in cocaine clinical trials. *College on Problems of Drug Dependence Annual Meeting*, San Juan, June 2004).

Kampman, K.M., Dackis, C.A., Lynch, K.G., Pettinati, H.M., Tirado, C., Atzram, M., Whittingham, T., O'Brien, C.P. Amantadine and Propranolol for the treatment of cocaine dependent patient with more severe cocaine withdrawal symptoms. *College on Problems of Drug Dependence Annual Meeting*, Orlando, Florida, June 2005.

Kampman, K.M., Pettinati, H.M., Macfadden, W., Lynch, K.G., Whittingham, T., Dackis, C.A., Varillo, K. A pilot trial of quetiapine for the treatment of alcohol dependence. College on Problems of Drug Dependence Annual Meeting, Scottsdale, Arizona, June 2006.

Starosta, A.N., Rha, C., Whittingham, D., DiDonato, K., Lynch, K., Kampman, K.M., Dackis, C.A. Factors involved in predicting the success of modafinil for the treatment of cocaine dependence. College on Problems of Drug Dependence Annual Meeting, Scottsdale, Arizona, June 2006.

Kampman, K.M., Lynch, K.G., Pettinati, H.M., Dackis, C.A., Dundon, W., Varillo, K., Fairbairn, C., Yama, M., O'Brien, C.P. The measurement of craving in cocaine pharmacotherapy trials: what do we learn from it? College on Problems of Drug Dependence Annual Meeting, Quebec City, Quebec, June 2007).

Dackis, C.A. Modafinil treatment for cocaine dependence. Cognitive Enhancers Symposium (Chair: Nora Volkow). American College of Neuropsychopharmacologists, Hollywood, Florida, December 2009).

PRESENTATIONS

"Hypothyroidism and depression," World Psychiatric Conference, New York, 1981.

"DST and TRH testing for depression in alcoholics," Special Committee on the Problems of Drug Abuse, Toronto, 1982.

"Depression in opiate addicts," National Association of Private Psychiatric Hospitals, First Annual Research Conference, Washington, D.C., 1983.

"Depression in alcoholics and opiate addicts," American Psychiatric Association Meeting, New York, 1983.

"Neuroendocrine testing of alcoholics for depression," American Psychiatric Association Meeting, New York, 1983.

"Platelet serotonin inhibition by cocaine," Special Committee on the Problems of Drug Abuse, St. Louis, 1984.

"TRH blunting in cocaine abusers," Special Committee on the Problems of Drug Abuse, St. Louis, 1984.

"TRH testing of cocaine abusers," American Psychiatric Association Meeting, Los Angeles, 1984.

"Hyperprolactinemia in cocaine abusers," Society for the Neurosciences, Anaheim, 1984.

"Neurochemical disruptions in cocaine abuse," Columbia University Symposium, New York, 1985.

"Dopamine deficiency in cocaine abuse," American Psychiatric Association Meeting, Dallas, 1985.

"Diagnosing depression in alcoholics," American Psychiatric Association Meeting, Dallas, 1985.

"Dopamine depletion hypothesis of cocaine addiction," American Academy of Clinical Psychiatrists, San Francisco, 1985.

"Brain mechanisms and pharmacological treatment in cocaine abuse," First National Conference: The Cocaine Challenge, New York, 1985.

"Affective disorders: identification and treatment," Science and the Mind, Mental Health Association in Delaware, Wilmington, 1985.

"Cocaine update," Emory University School of Medicine and Georgia State Drug Information Center, Atlanta, 1986.

"Bromocriptine treatment for cocaine craving," American Psychiatric Association Meeting, Washington, D.C., 1986.

"Controlling drug abuse in the workplace," Pitney, Hardin, Kipp, and Szuch Seminar, Princeton, NJ, 1986.

"Drug-induced psychopathology in substance abusers," American Psychiatric Association Meeting, Chicago, 1987.

"Cocaine addiction: current issues," Middle Atlantic-Great Lakes Organized Crime Law Enforcement Network, Cherry Hill, NJ, 1987.

"Drugs in the workplace," Princeton Area Chamber of Commerce, Princeton, NJ, 1987.

"Cocaine: medical and brain effects," American Psychiatric Association Meeting, Montreal, Canada, 1988.

"The dopamine depletion hypothesis," Federation of American Societies for Experimental Biology, Las Vegas, 1988.

"Neurobiology of cocaine craving," American Medical Society on Alcoholism and Other Dependencies, Atlanta, 1989.

"Pharmacological treatment of cocaine addiction in the 1990's" Pan American/World Health Organization, Huntington Hospital, Oreland, PA 1989.

"Pharmacological strategies for the 1990's" New Beginnings Medical Seminar, Lakehurst, NJ 1990.

"Dopamine agonists: bromocriptine and amantadine," ASAM Medical-Scientific Conference, Phoenix, 1990.

"Biochemical basis of successful drug treatments," Drug Abuse Conference, Princeton, 1990.

"The chemistry of neurotransmitters," Special Committee on Alcohol and Drug Abuse of the Physicians' Health Program of the Medical Society of NJ and the Academy of Medicine of NJ, Lawrenceville, NJ 1991.

"New treatment for cocaine addiction," First Annual Summit on Crack/Cocaine, Houston, Texas, 1991.

"Habitrol treatment of nicotine addiction," South Jersey Medical Society, Voorhees, NJ 1993.

"Modafinil treatment of cocaine dependence – theoretical basis," Treatment Research Center Scientific Advisory Committee, Philadelphia, PA, November 1999

"Modafinil – cocaine safety study: A double blind, placebo-controlled drug interaction study," Treatment Research Center, Scientific Advisory Committee, Philadelphia, PA, November 2000

"Ethical issues related to managed care," Friend's Hospital Symposium on Managed Care, Philadelphia, PA, April 2001

"Modafinil-cocaine drug interaction study," Annual College for Problems in Drug Dependence Meeting, Scottsdale, AR, June 2001

"New initiatives in clinical practice within an academic institution" Second Annual Conference of the Academic Behavioral Health Consortium (ABHC). Baltimore, Maryland, June 2001, Health system strategies: successes and failures.

"Modafinil – cocaine safety study; A double blind, placebo-controlled drug interaction study." Annual College for Problems in Drug Dependence Meeting, Scottsdale, Arizona, June 2001

"Principles of detoxification," Children's Hospital of Philadelphia, Department of Pediatrics, Philadelphia, PA, July 2001

"Modafinil-cocaine safety study, results of intravenous cocaine infusions in combination with modafinil pretreatment," National Institute on Drug Abuse, Rockville, MD, November 2001

"Cocaine – modafinil pilot study," National NIDA P50 Grant Meeting, November 2001

"Brief inpatient stabilization for cocaine dependence," Treatment Research Center, Scientific Advisory Committee, Philadelphia, PA, January 2002

Charles A. Dackis, M.D.

“Modafinil treatment for cocaine dependence,” National Institute on Drug Abuse, New York, November 2002

“An open-label trial of modafinil for cocaine dependence,” American Psychiatric Association, San Francisco, 2003

“Glutamatergic agents for cocaine dependence.” New York Academy of Science, New Haven, April 2003

“Modafinil Treatment for Cocaine Dependence,” Annual College for Problems in Drug Dependence Meeting, Bal Harbor, June 2003

“Cocaine – modafinil double blind study,” National NIDA P50 Grant Meeting, Washington, D.C., January 2004

“Keynote Address – Modafinil Multicenter Study Kickoff Meeting,” NIDA, Bethesda, June, 2004

“Pharmacological strategies for cocaine dependence,” College of Problems of Drug Dependence, Orlando, Florida, June 2005

“Neurobiology of Alcohol Dependence,” Crozer-Chester Medical Center, Upland, Pennsylvania, July 2006

“Interventions for Cocaine,” University of Pennsylvania Department of Psychiatry Grand Rounds, November 2006

“Review of studies on modafinil treatment for cocaine dependence,” National Institute of Drug Abuse/NIH Symposium, Miami, Florida, April 2007

“Modafinil: “Abuse potential and role in cocaine dependence,” American College of Neuropsychopharmacology, Hollywood, Florida, December 2009

“Cognitive Enhancers,” American Psychiatric Association, New Orleans, May 2010.

SERVED AS JOURNAL REFEREE

Addiction Biology

Alcoholism

American Journal of Psychiatry

Archives of Internal Medicine

Archives of General Psychiatry

Biological Psychiatry

Bipolar Disorders

Comprehensive Psychiatry

Drug and Alcohol Dependence

Charles A. Dackis, M.D.

Journal of the American Medical Association
Journal of Nervous and Mental Disease
Journal of Substance Abuse Treatment
Neuropsychopharmacology
New England Journal of Medicine
Pharmacology Biochemistry and Behavior
Psychopharmacology and Biological Psychiatry
Psychiatry Research
Psychoneuroendocrinology
Trends in Pharmacological Sciences

Revised: January 2010